Figure 4

Treatment with ZA does not improve survival. Mice were divided into two groups (n=10 mice per group). Mice were treated daily with s.c. ZA (100 μg kg⁻¹, ∼2.5 μg per mice) or PBS injections starting on day 5 after tumour injection. This dosing schedule was proven effective and non-toxic (Stathopoulos et al, 2008). Mice were killed when found profoundly ill. No significant improvement of survival was measured. (A) Kaplan–Meier survival curve. No significant differences in survival were observed between mice treated daily with s.c. injection of ZA compared with untreated mice (P=0.3675). (B) Malignant effusions and tumour weights. Tumour weight and the amount of malignant effusion were measured when mice were killed. The effusion fluid was removed from the peritoneal cavity by fine-needle aspiration and all visible tumour material was collected. No significant differences in tumour weight or the amount of malignant effusion were observed (P=0.42 and 0.61). (C) Myeloid cell types in the spleen of tumour-bearing mice. Long-term treatment effects were observed in the number of myeloid cells within the spleen of tumour-bearing mice, implicating that higher numbers of myeloid precursors and lower numbers of TAMs were detected in mice treated with ZA compared with untreated mice.